Cargando…

Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer

OBJECTIVE: To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis. PATIENTS AND METHODS: A two cohort based evaluation for serum CGA for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giridhar, Karthik V., Sanhueza, Cristobal, Hillman, David, Alkhateeb, Hassan, Carlson, Rachel, Tan, Winston, Costello, Brian A., Quevedo, Fernando, Pagliaro, Lance, Kohli, Manish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126956/ https://www.ncbi.nlm.nih.gov/pubmed/29858590 http://dx.doi.org/10.1038/s41391-018-0046-9

Ejemplares similares

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma
por: Giridhar, Karthik V., et al.
Publicado: (2017)

Chromogranin A: a useful biomarker in castration-resistant prostate cancer
por: Ploussard, Guillaume, et al.
Publicado: (2022)

Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer
por: Du, Meijun, et al.
Publicado: (2020)

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Binder, Moritz, et al.
Publicado: (2016)

Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
por: Hong, Peng, et al.
Publicado: (2018)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients
por: Kohli, Manish, et al.
Publicado: (2018)

A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens
por: Jimenez, Rafael E., et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
por: Du, Meijun, et al.
Publicado: (2017)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
por: Du, Meijun, et al.
Publicado: (2020)

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors — a major reason for enhanced chemosensitivity?
por: Shenoy, Niraj, et al.
Publicado: (2017)

Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer
por: Huang, Zhuo, et al.
Publicado: (2023)

Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer
por: Huang, Jinyong, et al.
Publicado: (2022)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2017)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis
por: Guo, Zhenlang, et al.
Publicado: (2019)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
por: Mak, Blossom, et al.
Publicado: (2022)

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
por: Kohli, Manish, et al.
Publicado: (2020)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach
por: Deng, Detian, et al.
Publicado: (2016)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
por: Mitsui, Yozo, et al.
Publicado: (2023)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
por: Wengel Mogensen, Søren, et al.
Publicado: (2016)

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients
por: Zhu, Sha, et al.
Publicado: (2021)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vm52466nah6jq8ajoaaik7ukth